Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with unknown aetiology. According to the role of interleukin 10 (IL10) in SLE pathogenesis, the genetic alterations in its promoter region could be associated with elevated IL10 levels and exacerbated disease. Here, we investigated the association of genotype and hap- 
| INTRODUC TI ON
Systemic lupus erythematosus (SLE) is a complex and chronic autoimmune disorder which is accompanied by the extensive production of autoantibodies and deposition of immune complexes in damaged organs (Tunnicliffe, Singh-Grewal, Kim, Craig, & Tong, 2015; Yurkovich, Vostretsova, Chen, & Aviña-Zubieta, 2014) . Although the exact aetiology of SLE is still unknown, both environmental and genetic factors could be involved in the development and propagation of SLE (Lo & Tsokos, 2017) . However, the higher concordance rate in monozygotic twins and increased risk of SLE in relatives highlight the genetic factors in SLE pathogenesis (Kuo et al., 2016) . Various genes have been suggested as SLE predisposing factors which are commonly known as "SLE susceptibility genes" such as human leucocyte antigen (HLA) (Armstrong et al., 2014) , mannose-binding lectin (MBL) (Tanha et al., 2014) , Fc gamma receptor (FcγR) (Tsang-A-Sjoe et al., 2016) and programmed cell death-1 (PD-1) (Gianchecchi, Delfino, & Fierabracci, 2013) . Moreover, the cytokine production by immune cells is aberrantly imbalanced in SLE which may be associated with exacerbated immune response and increased disease severity (Jacob & Stohl, 2011) . These alterations are mostly observed among cytokines with polymorphic gene sequences (Mohammadoo-khorasani et al., 2016) .
Interleukin 10 (IL10) is a multifunctional and immunoregulatory cytokine which is mainly produced by monocytes and B lymphocytes (Beebe, Cua, & de Waal Malefyt, 2002) . Although IL10 is considered to exert anti-inflammatory effects by inhibiting the synthesis of pro-inflammatory cytokines in activated macrophages and T lymphocytes (Groux & Cottrez, 2003) , it plays a crucial role in SLE pathogenesis by enhancing the proliferation and differentiation of B lymphocytes and increasing the production of autoantibodies in damaged tissues (Dörner, Jacobi, & Lipsky, 2009; Peng et al., 2013) . Accordingly, the elevated levels of IL10 have been correlated with the increased activity of SLE in several studies (Godsell et al., 2016) .
The expression of IL10 as a SLE susceptibility gene is regulated by its promoter region which is highly polymorphic (Iyer & Cheng, 2012) .
Previous studies have reported that single nucleotide polymorphisms (SNPs) in the promoter region of IL10 could be accompanied by altered expressions of its cytokine and subsequent associations with the susceptibility to SLE (Chong et al., 2004; Palafox-Sánchez et al., 2015) .
Three SNPs at the positions of −1082 (rs1800896), −819 (rs1800871) and −592 (rs1800872) have been confirmed to associate with the increased susceptibility to SLE and IL10 expression (Chong et al., 2004; Palafox-Sánchez et al., 2015; Rianthavorn, Chokedeemeeboon, Deekajorndech, & Suphapeetiporn, 2013) . 
| MATERIAL S AND ME THODS

| Patients and controls
A total of 116 patients fulfilling the revised criteria of the American College of Rheumatology (ACR) for SLE were enrolled in this study from Rheumatology Department, Sayyad Shirazi Educational Hospital, Gorgan, Iran. The primary diagnosis and clinical manifestations were confirmed, and SLE Disease Activity Index (SLEDAI) scores were derived by an expert rheumatologist. A total of 131 healthy donors were also recruited. Quanto test (https://biostats.usc.edu/ cgi-bin/DownloadQuanto.pl) was used for power calculations, and it was set at the average level of 0.78 (Gauderman, 2002; Gauderman & Morrison, 2006) . A written informed consent following the declaration of Helsinki (Goodyear, Krleza-Jeric, & Lemmens, 2007) was signed and taken from all participants. Clinical characteristics and laboratory data of SLE patients and healthy subjects are shown in Table 1 . A volume of 5 ml whole blood was obtained from all individuals at the time of clinical examination and transferred to the laboratory. Plasma was isolated immediately and kept at −80ºC for the measurement of IL10. Peripheral blood mononuclear cells (PBMCs)
were separated using Ficoll-Paque (Baharafshan, Tehran, Iran) density gradient centrifugation.
| DNA extraction and genotyping
Genomic DNA was extracted from PBMCs using a genomic DNA isolation kit (Dena Zist, Iran) according to the manufacturer's protocols. The DNA samples were then stored at −20ºC until use. The polymerase chain reaction (PCR) was used to amplify the polymorphic regions, and restriction fragment length polymorphism (RFLP) TA B L E 1 Clinical characteristics and laboratory parameters of systemic lupus erythematosus patients and healthy subjects Finally, the undigested PCR products of −592 (C/A) with 412 bp represented C allele. The presence of A allele was confirmed by visualizing two fragments of digested PCR product with 176 and 236 bp.
| ELISA cytokine assay
A commercially available ELISA kit (BioLegend, USA) was used to evaluate the plasma level of IL10 in SLE patients. All samples were examined in triplicates. The results were reported as picograms per ml. Biotek ELISA reader ELX 800 (Biotek, USA) was used to obtain optical density of all samples at the wavelength of 450 nm.
| Statistical analyses
The Table 5 .
TA B L E 3 The genotype and allele frequencies of IL10 -1082 (G/A) SNP in systemic lupus erythematosus (SLE) patients and healthy subjects under different inheritance models suggesting an increased risk of SLE in these haplotypes (Table 6) .
We also analysed the interaction of tested SNPs and association of all haplotype frequencies with SLE susceptibility by SNPstats. The We also evaluated the IL10 plasma levels among constructed haplotypes and showed that IL10 is significantly elevated among CGT (−592/−1082/−819) carriers (p = 0.025). There were no other significant differences between the remaining haplotypes and IL10 plasma expression.
| The disease activity is different in IL10 gene promoter genotypes and haplotypes
We examined the association of IL10 gene promoter genotypes and haplotypes with the calculated SLEDAI scores of patients. As
TA B L E 4 The genotype and allele frequencies of IL10 -819 (C/T) SNP in SLE patients and healthy subjects under different inheritance models
Genotypes and alleles SLE patients (n = 116) Number (%)
Normal subjects (n = 131) Number (%) 
| D ISCUSS I ON
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with unknown aetiology which could be accompanied by various clinical manifestations from mild to moderate cutaneous involvements to lifethreatening damages in vital organs (Tunnicliffe et al., 2015; Yurkovich et al., 2014) . Similar to other autoimmune disorders, the genetic factors including "SLE susceptibility genes" have been proposed to be involved in SLE pathogenesis (Armstrong et al., 2014) . While cytokine expression is imbalanced, the genetic alterations in the promoter regions of cytokines are of great importance in SLE initiation and propagation (Jacob & Stohl, 2011) . IL10 is a multifunctional cytokine which is considered to exert anti-inflammatory effects by inhibiting the synthesis of pro-inflammatory cytokines (Groux & Cottrez, 2003) . However, it is also involved in SLE pathogenesis, and several studies have reported the elevated levels of IL10 in exacerbated disorders (Godsell et al., 2016) . It has been suggested that certain SNPs in the promoter region of IL10 could be associated with the elevated expression of its cytokine and increased susceptibility to various inflammatory and autoimmune disorders such as asthma (Gao et al., 2015) , rheumatoid arthritis (RA) (Gambhir et al., 2010; Nemec et al., 2009 ) and SLE (Liu et al., 2013; Palafox-Sánchez et al., 2015) . In the present study, we evaluated the association of genotype and haplotype frequencies of three distinct IL10 gene promoter polymorphisms including −1082 (rs1800896), −819 (rs1800871) and −592 (rs1800872) with susceptibility to SLE, IL10 expression and disease activity of patients in an Iranian population.
Although no study has investigated the association between the IL10 -592 (C/A) polymorphism and SLE susceptibility in Iran, several studies have provided controversial and heterogeneous reports in other regions. Here, we found that the AA genotype and A allele were significantly associated with the decreased risk of SLE. Our findings were in accordance with Chong et al (Chong et al., 2004) and Rianthavorn et al (Rianthavorn et al., 2013) who reported the increased CC and decreased AA genotypes in two distinct populations. However, several studies which were mostly conducted on Caucasians have reported no significant association (Abdallah, Waked, & Abdelwahab, 2016; Guzowski et al., 2005; Suárez, López, Mozo, & Gutiérrez, 2005) or even introduced C allele as a protective allele (Lin et al., 2010) . In accordance with recent studies Zhou et al., 2013) , we
showed that the increased GG genotype and G allele of the IL10 -1082
(G/A) polymorphism in patients were associated with SLE susceptibility. Regarding IL10 -819 (C/T) SNP, we showed that CC genotype was associated with the increased risk of SLE and the frequency of C allele was related to SLE susceptibility. Although some controversial reports with non-significant results are available (Palafox-Sánchez et al., 2015) , our findings were confirmed in previous studies (Chong et al., 2004; Rosado et al., 2008; Talaat, Alrefaey, Bassyouni, Ashour, & Raouf, 2016) . haplotypes were associated with the increased risk of SLE. Although such pairwise comparisons were rare in previous findings, these associations could be implemented from Kurreeman et al (Kurreeman, Schonkeren, Heijmans, Toes, & Huizinga, 2004) and Chong et al (Chong et al., 2004) . Analysing the interaction of tested SNPs revealed heterogeneous LD in the IL10 SNPs with the strongest LD between −819 and −592 and the absence of LD between −819 and other SNPs.
While other studies have not investigated the linkage of these SNPs in
Iranian population, further studies should be conducted to confirm or reject our findings. The association of all haplotypes showed that CAC carriers (−592/−1082/−819) were more susceptible to SLE which was also mentioned in previous findings (Kurreeman et al., 2004; PalafoxSánchez et al., 2015; Zhou et al., 2013) . We also found that IL10 plasma levels were increased in SLE patients with CC genotype (−592) and decreased among AA genotype carriers (−1082) in comparison with other genotypes in the same group which were in accordance with Palafox-Sanchez et al (Palafox-Sánchez et al., 2015) who reported the association of CC (−592) genotype with the elevated IL10. Our findings were in contrast to Talaat et al (Talaat et al., 2016) who showed that AA and GA genotypes in relation to −819 (G/A) SNP are associated with the increased IL10 levels. In order to bring more compelling data on the expression alterations of IL10 in the studied SNPs, Genotype-Tissue Expression (GTEx) programme (https://www.gtexportal.org/) was employed. The expression of IL10 had been studied in association with all three SNPs on human whole blood sample tissues. The results were in accordance with our findings, and the mRNA expression of IL10 was elevated in altered homozygous genotypes, decreased in heterozygous and represented the lower levels in homozygous reference genotypes (Lonsdale et al., 2013) . Similar to most of the previous reports (PalafoxSánchez et al., 2015; Rianthavorn et al., 2013; Talaat et al., 2016) in the studies which have reported the association of these genotypes and haplotypes with SLE susceptibility (Chong et al., 2004; Palafox-Sánchez et al., 2015; Rianthavorn et al., 2013; Talaat et al., 2016) . Our study was also associated with some limitations.
The power of the test was set at the level of 0.8, and it was actually calculated 0.78 using Quanto test. The power could be enhanced by increasing the sample size to overcome this limitation.
F I G U R E 1 Association assessment of IL10 -592 (C/A) (a), −1082 (G/A) (b) and −819 (C/T) (c) genotypes with IL10 plasma levels according to co-dominant, dominant and recessive models; statistical analysis was performed using independent samples Kruskal-Wallis test followed by Dunn-Bonferroni post hoc test. Each bar represents means ± SE. p-values lower than 0.05 were considered as statistically significant
Moreover, no subgroup analysis was conducted regarding treatment responses and strategies or relapsing or remitting patients.
These measures in addition to sequencing the polymorphic regions of interest could be used to improve the quality of future studies.
| CON CLUS ION
Our findings revealed that the IL10 gene promoter polymorphisms at the positions of −1082 (rs1800896), −819 (rs1800871) and −592 (rs1800872) could be associated with the susceptibility to SLE, disease activity and increased IL10 levels in an Iranian population.
According to the fact that there are no previous reports about the association of IL10 gene promoter polymorphisms and SLE in Iran, the differences in allele, genotype and haplotype frequencies and associations may be due to ethnic variations. Although the present study together with the previous reports contribute to understand the genetic susceptibility of SLE, further clinical and molecular studies are needed to better elucidate the role of IL10 gene promoter polymorphisms in SLE pathogenesis.
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